In short
This article discusses a clinical trial investigating the use of a drug containing Ovolecithin, along with other substances, in treating children with Long-chain Fatty Acid Oxidation Disorders (LC-FAOD). The study aims to compare the effects of triheptanoin with medium-chain triglycerides (MCT) on major clinical events in pediatric patients with LC-FAOD.
At a glance
- Study Type
- Randomized, double-blind, multicenter study
- Condition
- Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
- Age Group
- 0 to <18 years
- Investigational Drug
- Triheptanoin (contains Ovolecithin)
- Control Drug
- Medium-chain Triglycerides (MCT)
- Primary Objective
- Evaluate effect on frequency of Major Clinical Events (MCEs)
- Secondary Objectives
- Assess duration of MCEs, frequency of hypoglycemic events, change in overall health status, effect on cardiomyopathy MCEs, and more
- Administration
- Oral use
- Maximum Daily Dose
- 35%
- Maximum Treatment Period
- 24 months
What is OVOLECITHIN?
OVOLECITHIN, also known as egg lecithin, is a component of a medical product being studied for the treatment of Long-chain Fatty Acid Oxidation Disorders (LC-FAOD). It is part of a fat emulsion that includes other substances such as glycerol, doconexent (also called docosahexaenoic acid), icosapent (also known as eicosapentaenoic acid), and DL-alpha-tocopherol (a form of vitamin E).
Understanding Long-chain Fatty Acid Oxidation Disorders (LC-FAOD)
Long-chain Fatty Acid Oxidation Disorders (LC-FAOD) are a group of rare genetic metabolic conditions. In these disorders, the body has difficulty breaking down certain fats into energy, particularly during periods without food (fasting) or during illness. This can lead to various health problems, including:
- Hypoglycemia (low blood sugar)
- Rhabdomyolysis (breakdown of muscle tissue)
- Cardiomyopathy (heart muscle disease)
These conditions can be severe and potentially life-threatening, especially in children.
Clinical Trial Information
A clinical trial (study number 2023-509809-76-00) is being conducted to evaluate a new treatment approach for children with LC-FAOD. This study is comparing two treatments:
- Triheptanoin: An investigational drug
- Medium-chain Triglycerides (MCT): A type of fat that's easier for people with LC-FAOD to process
The product containing OVOLECITHIN is part of the MCT treatment in this study.
Treatment Approach
The treatment being studied is an oral liquid that contains medium-chain triglycerides (MCT). This fat emulsion includes OVOLECITHIN along with other components. The maximum daily dose is 35% of the patient's total caloric intake.
The idea behind this treatment is to provide an alternative energy source that can be more easily processed by individuals with LC-FAOD, potentially reducing the frequency and severity of metabolic crises.
Eligibility Criteria
The study is focused on children with LC-FAOD. Some key eligibility criteria include:
- Confirmed diagnosis of LC-FAOD
- Age from 0 (including newborns) to less than 18 years
- History of significant clinical manifestations of LC-FAOD, such as metabolic crises or susceptibility to hypoglycemia
There are additional criteria for inclusion and exclusion in the study, which a healthcare provider can explain in detail.
Study Objectives and Endpoints
The main goal of the study is to evaluate how effective the treatment is in reducing the frequency of major clinical events (MCEs) related to LC-FAOD. Other objectives include:
- Assessing the effect on the duration of MCEs
- Evaluating the impact on hypoglycemic events
- Measuring changes in overall health status and functioning
- Assessing the effect on cardiomyopathy events
The study will also look at quality of life measures and the safety of the treatment.
Potential Benefits and Considerations
While the specific benefits of OVOLECITHIN in this treatment are not detailed, the overall approach aims to provide a more easily metabolized energy source for children with LC-FAOD. This could potentially lead to:
- Fewer metabolic crises
- Reduced frequency and severity of symptoms
- Improved quality of life
However, as with any medical treatment, there may be risks and side effects. The study is designed to carefully monitor participants for any adverse events.
It's important to note that this is an investigational treatment, and its effectiveness and safety are still being evaluated. Patients and caregivers should discuss the potential benefits and risks with their healthcare providers.